MedTrace Logo

Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients

NCT07450300 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1831

Last updated 2026-03-04

No results posted yet for this study

Summary

This retrospective study included 1,831 single blastocyst frozen embryo transfer (FET) cycles performed between November 1, 2022 and August 31, 2025. Three endometrial preparation protocols were used according to ovulatory status, cycle duration, and characteristics of previous FET cycles: modified natural cycle with ovulation trigger (mNC-FET) (n = 770), stimulated cycle FET (SC-FET) (n = 468), and hormone replacement therapy FET (HRT-FET) (n = 593). In natural cycles, if the predefined criteria for ovulation trigger were not met, the cycle was converted to a stimulated cycle. The aim of this study was to determine whether body mass index affects embryo transfer feasibility, reproductive outcomes, and cycle characteristics across different FET protocols.

Conditions

  • Infertility, Female

Interventions

PROCEDURE

Modified natural cycle

In the modified natural cycle group, patients underwent ultrasound and hormonal monitoring to track spontaneous follicular development. When the leading follicle reached an appropriate size and endometrial thickness was adequate, ovulation was triggered using human chorionic gonadotropin (hCG) to schedule frozen embryo transfer.

PROCEDURE

Substitued cycle

In the stimulated cycle group, mild ovarian stimulation was performed using oral agents and/or low-dose gonadotropins to promote follicular development. Follicular growth was monitored by ultrasound, and ovulation was either triggered with hCG or occurred spontaneously, allowing scheduling of frozen embryo transfer.

PROCEDURE

Hormonal replacement therapy

In the hormone replacement therapy group, endometrial preparation was achieved through exogenous estrogen administration. Once adequate endometrial thickness was confirmed, progesterone supplementation was initiated to mimic the luteal phase and schedule frozen embryo transfer.

Sponsors & Collaborators

  • Clinique Mathilde

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2025-08-31
Completion
2026-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07450300 on ClinicalTrials.gov